The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
 
Jean-Christophe Pignon
No Relationships to Disclose
 
Opeyemi Jegede
No Relationships to Disclose
 
Kathleen M. Mahoney
No Relationships to Disclose
 
Raphael Brandao Moreira
No Relationships to Disclose
 
Jesse Novak
No Relationships to Disclose
 
Hilla Conen
No Relationships to Disclose
 
Craig Norton
No Relationships to Disclose
 
Lauren Christine Harshman
Consulting or Advisory Role - Dendreon; Genentech; KEW; Medivation/Astellas; NCCN; Pfizer; PlatformQ Health; Theragene
Research Funding - Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Medivation/Astellas (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - Syapse
Consulting or Advisory Role - Novartis; Roche; Syapse; Takeda; Third Rock Ventures
Research Funding - Bristol-Myers Squibb
 
Catherine J. Wu
Stock and Other Ownership Interests - Neon Therapeutics; Neon Therapeutics (I)
Consulting or Advisory Role - Cell Signaling Technology; Cell Signaling Technology (I); Neon Therapeutics; Neon Therapeutics (I)
Research Funding - EMD Serono (I); Janssen (I); Pfizer (I)
Patents, Royalties, Other Intellectual Property - Neon Therapeutics; Neon Therapeutics (I)
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Alkermes; Amgen; Bristol-Myers Squibb; C-Cam; Genentech; Genoptix; GlaxoSmithKline; Infinity Pharmaceuticals; Lilly; Merck; Nektar; Novartis; Pfizer; X4 Pharma
 
Gordon J. Freeman
Consulting or Advisory Role - Bethyl Laboratories; Bristol-Myers Squibb; Lilly; Novartis; Novartis (I); Quiet Therapeutics; Roche/Genentech; Seagen; Surface Oncology (I); Xios Therapeutics
Research Funding - Novartis (I); Roche/Genentech (I)
Patents, Royalties, Other Intellectual Property - Amplimmune/Astrazeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; EMD Serono; Merck; Novartis; Novartis (I); Pfizer (I); Roche/Genentech; Roche/Genentech (I)
 
Paul J. Catalano
Research Funding - Lilly/ImClone
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca; Merck; Verastem
Patents, Royalties, Other Intellectual Property - Biogenex